LONDON (ShareCast) - (Sharecast News) - Hikma Pharmaceuticals announced on Tuesday that its Hikma Pharmaceuticals USA division, formerly known as West-Ward Pharmaceuticals, has launched Mitomycin for Injection, USP' at dosages of 20mg and 40mg.
The FTSE 100 company said Mitomycin for Injection, USP was not recommended as single-agent, primary therapy.

It had been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents, and as palliative treatment when other modalities had failed.

Mitomycin was not recommended to replace appropriate surgery or radiotherapy.

According to IQVIA, US sales of Mitomycin for Injection were approximately $43m in the 12 months ending November 2018.

"We are excited to add Mitomycin for Injection to our oncology portfolio in the US, improving patients' access to this important medicine," said Hikma's president of injectables Riad Mechlaoui.

"This demonstrates the successful execution of our strategy to expand our portfolio in key therapeutic areas."

The board said the new product introduction expanded its "broad" US offering of more than 90 injectable products, and further solidified its position as one of the top three suppliers of generic injectable products to US hospitals.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE